This Weekly’s Hot Topics
- Oncologist, Dr. Stephen Hahn, to lead the FDA. National News
- CVS Health launching new precision medicine strategy for payers. National News
- CMS extending Affordable Care Act open-enrollment period. CMS News
CancerCare has created the “California Wildfires Patient Assistance Program” for cancer patients impacted by the California wildfires. The program offers:
– Financial assistance to people living with cancer in active treatment who have been affected by a wildfire;
– Resource referrals to help people coping with cancer, addressing needs resulting from a wildfire’s impact;
– Emotional support from CancerCare oncology social workers for people coping with cancer, their caregivers and their loved ones;
– Educational information to help patients and families manage the emotional and logistical challenges of living with cancer. To read more click here and go to California News.
Starting January 1, if you do not use the MBI (regardless of the date of service) for Medicare transactions Noridian will reject your claims with a few exceptions and Noridian will reject all eligibility transactions. To read more click here and go to Noridian News.
Group practices or individual eligible clinicians interested in applying for a hardship exception to the promoting interoperability category or an extreme and uncontrollable circumstances exception to other MIPS categories for the 2019 performance year must submit an application by Dec. 31. To read more click here and go to CMS News.
ASCO is pleased to announce the official launch of the ABIM/ASCO Medical Oncology: Learning & Assessment (MOLA), a flexible, lower stakes maintenance of certification (MOC) program that offers physicians a choice of medical oncology assessments–either a general medical oncology assessment or disease-specific medical oncology assessments (e.g., breast cancer, hematologic malignancies). To read more click here and go to Affiliate Association News.
To read the complete California Oncology Weekly Newsletter, click on the date below.